Acetylsalicylic acid for the treatment of patients with cardiovascular diseases: new data, clinical guidelines and practical aspects

Capa

Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Millions of patients with cardiovascular diseases receive acetylsalicylic acid (ASA), but some of them have acute events despite the drug therapy. One of the backgrounds for the development of cardiovascular events in groups of increased cardiovascular risk may be the lack of response to standard low doses of ASA. In recent years, possible causes and risk factors for this phenomenon have been actively discussed, including its connection with the presence of an enteric coating in ASA drugs, as well as possible ways to overcome it by identifying the most vulnerable groups of patients for whom it is preferable to prescribe certain forms of ASA or individual dose selection. The article discusses new clinical studies devoted to this problem and the corresponding changes in the recommendation documents.

Texto integral

Acesso é fechado

Sobre autores

Alexandra Pisaryuk

RUDN University

Autor responsável pela correspondência
Email: pisaryuk_as@pfur.ru
ORCID ID: 0000-0003-4103-4322
Código SPIN: 5602-1059

MD, PhD (Medicine), associate professor of the Department of internal medicine with a course in cardiology and functional diagnostics named after academician V.S. Moiseyev of the Medical institute; cardiologist at the resuscitation and intensive care unit for cardiology patients, V.V. Vinogradov University Clinical Hospital

Rússia, 117198, Moscow, 6 Mikloukho-Maklaya St.

Xong Ly

RUDN University

Email: lyxongpha@mail.ru
ORCID ID: 0009-0004-0211-9678

MD, postgraduate student of the Department of internal medicine with the course of cardiology and functional diagnostics named after academician V.S. Moiseyev of the Medical institute

Rússia, 117198, Moscow, 6 Mikloukho-Maklaya St.

Aliya Amirova

RUDN University

Email: amirova-86@inbox.ru
ORCID ID: 0009-0000-2474-7297
Código SPIN: 4863-3280

MD, postgraduate student of the Department of internal medicine with the course of cardiology and functional diagnostics named after academician V.S. Moiseyev of the Medical institute

Rússia, 117198, Moscow, 6 Mikloukho-Maklaya St.

Zhanna Kobalava

RUDN University

Email: zkobalava@mail.ru
ORCID ID: 0000-0002-5873-1768
Código SPIN: 9828-5409
Scopus Author ID: 7004399203

MD, Dr. Sci. (Medicine), professor, corresponding member of RAS, head of the Department of internal medicine with a course in cardiology and functional diagnostics named after academician V.S. Moiseyev of the Medical institute; head of V.V. Vinogradov University Clinical Hospital

Rússia, 117198, Moscow, 6 Mikloukho-Maklaya St.

Bibliografia

  1. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329–39. PMID: 8918275. https://doi.org/10.1016/S0140-6736(96)09457-3
  2. The SYMPHONY investigators. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomised trial. Lancet. 2000;355(9201):337–45. PMID: 10665552. https://doi.org/10.1016/S0140-6736(99)11179-6
  3. Bousser M-G, Amarenco P, Chamorro A, Fisher M, Ford I, Fox KM et al. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): A randomised, double-blind, parallel-group trial. Lancet. 2011;377(9782):2013–22. PMID: 21616527. https://doi.org/10.1016/S0140-6736(11)60600-4
  4. Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR et al. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med. 2016;375(1): 35–43. PMID: 27160892. https://doi.org/10.1056/NEJMoa1603060
  5. Vranckx P, Valgimigli M, Jüni P, Hamm C, Steg PG, Heg D et al.; GLOBAL LEADERS Investigators. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: A multicentre, open-label, randomised superiority trial. Lancet. 2018;392(10151):940–49. PMID: 30166073. https://doi.org/10.1016/S0140-6736(18)31858-0
  6. Koo B-K, Kang J, Park KW, Rhee T-M, Yang H-M, Won K-B et al. ; HOST-EXAM investigators. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): An investigator-initiated, prospective, randomised, open-label, multicentre trial. Lancet. 2021;397(10293):2487–96. PMID: 34010616. https://doi.org/10.1016/S0140-6736(21)01063-1
  7. Patrono C. Low-dose aspirin for the prevention of atherosclerotic cardiovascular disease. Eur Heart J. 2024;45(27):2362–76. PMID: 38839268. PMCID: PMC11242460. https://doi.org/10.1093/eurheartj/ehae324
  8. Patrono C. Nonsteroidal antiinflammatory drugs. In: Hochberg MC, Gravallese EM, Smolen JS, van der Heijde D, Weinblatt ME, Weisman MH (eds.), Rheumatology. 8th edition. Elsevier. 2022:715–22. ISBN: 9780702081330.
  9. Gawaz M, Vogel S. Platelets in tissue repair: Control of apoptosis and interactions with regenerative cells. Blood. 2013;122(15):2550–54. PMID: 23963043. https://doi.org/10.1182/blood-2013-05-468694
  10. Rocca B, Fox KAA, Ajjan RA, Andreotti F, Baigent C, Collet J-P et al. Antithrombotic therapy and body mass: An expert position paper of the ESC Working Group on Thrombosis. Eur Heart J. 2018;39(19):1672–1686f. PMID: 29509886. https://doi.org/10.1093/eurheartj/ehy066
  11. Walker J, Cattaneo M, Badimon L, Agnelli G, Chan AT, Lanas A et al. Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: Benefits and risks of antithrombotic therapy for cardiovascular disease prevention. Ecancermedicalscience. 2020;14:998. PMID: 32153653. PMCID: PMC7032943. https://doi.org/10.3332/ecancer.2020.998
  12. Ebrahimi P, Farhadi Z, Behzadifar M, Shabaninejad H, Gorji HA, Mirghaed MT et al. Prevalence rate of laboratory defined aspirin resistance in cardiovascular disease patients: A systematic review and meta-analysis. Caspian J Intern Med. 2020;11(2):124–34. PMID: 32509239. PMCID: PMC7265510. https://doi.org/10.22088/cjim.11.2.124
  13. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin “resistance” and risk of cardiovascular morbidity: Systematic review and meta-analysis. BMJ. 2008;336(7637):195–98. PMID: 18202034. PMCID: PMC2213873. https://doi.org/10.1136/bmj.39430.529549.BE
  14. Cao J, Hao W-J, Gao L-G, Chen T-M, Liu L, Sun Y-F et al. Establishing a predictive model for aspirin resistance in elderly Chinese patients with chronic cardiovascular disease. J Geriatr Cardiol. 2016;13(5):458–64. PMID: 27594876. PMCID: PMC4984570. https://doi.org/10.11909/j.issn.1671-5411.2016.05.003
  15. Liu Q, Guo S, Wang N, Wang K, Mo S, Li X et al. Model based on single-nucleotide polymorphism to discriminate aspirin resistance patients. Stroke Vasc Neurol. 2024;9(3):212–20. PMID: 37586776. PMCID: PMC11221311. https://doi.org/10.1136/svn-2022-002228
  16. Ma T, Wang X, Song Y, Liu J, Zhang M. Construction and evaluation of an aspirin resistance risk prediction model for ischemic stroke. BMC Neurol. 2025;25(1):244. PMID: 40474099. PMCID: PMC12139116. https://doi.org/10.1186/s12883-025-04267-5
  17. Кобалава Ж.Д., Писарюк А.С., Филькова А.А., Тухсанбоев Е.С., Болдырева А.А., Лазутова Д.П. с соавт. Фенотипы тромбоцитов и практические аспекты методов тестирования функции тромбоцитов в кардиологии. Рациональная фармакотерапия в кардиологии. 2023;19(6):614–627. [Kobalava ZhD, Pisaryuk AS, Filkova AA, Tukhsanboev ES, Boldyreva AA, Lazutova DP et al. Platelet phenotypes and practical aspects of platelet function testing in cardiology. Ratsional’naya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology. 2023;19(6):614–627 (In Russ.)]. EDN: KAAWKP. https://doi.org/10.20996/1819-6446-2023-2981
  18. Clerici B, Cattaneo M. Pharmacological efficacy and gastrointestinal safety of different aspirin formulations for cardiovascular prevention: A narrative review. J Cardiovasc Dev Dis. 2023;10(4):137. PMID: 37103016. PMCID: PMC10145431. https://doi.org/10.3390/jcdd10040137
  19. Cofer LB, Barrett TJ, Berger JS. Aspirin for the primary prevention of cardiovascular disease: Time for a platelet-guided approach. Arterioscler Thromb Vasc Biol. 2022;42(10):1207–16. PMID: 36047408. PMCID: PMC9484763. https://doi.org/10.1161/atvbaha.122.318020
  20. McCall M, Peace A, Tedesco AF, Foley D, Conroy RM, Cox D. Weight as an assay-independent predictor of poor response to enteric aspirin in cardiovascular patients. Platelets. 2020;31(4):530–35. PMID: 31530207. https://doi.org/10.1080/09537104.2019.1667495
  21. Maree AO, Curtin RJ, Dooley M, Conroy RM, Crean P, Cox D, Fitzgerald DJ. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol. 2005;46(7):1258–63. PMID: 16198840. https://doi.org/10.1016/j.jacc.2005.06.058
  22. Cox D, Maree AO, Dooley M, Conroy R, Byrne MF, Fitzgerald DJ. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke. 2006;37(8):2153–58. PMID: 16794200. https://doi.org/10.1161/01.STR.0000231683.43347.ec
  23. Bhatt DL, Grosser T, Dong J-F, Logan D, Jeske W, Angiolillo DJ et al. Enteric coating and aspirin nonresponsiveness in patients with type 2 diabetes mellitus. J Am Coll Cardiol. 2017;69(6):603–12. PMID: 28089180. https://doi.org/10.1016/j.jacc.2016.11.050
  24. Elshafei MN, Imam Y, Alsaud AE, Chandra P, Parray A, Abdelmoneim MS et al. The impact of enteric coating of aspirin-on-aspirin responsiveness in patients with suspected or newly diagnosed ischemic stroke: Prospective cohort study: Results from the (ECASIS) study. Eur J Clin Pharmacol. 2022;78(11):1801–11. PMID: 36121499. PMCID: PMC9546947. https://doi.org/10.1007/s00228-022-03391-2
  25. Seecheran N, McCallum P, Grimaldos K, Ramcharan P, Kawall J, Katwaroo A et al. Pharmacodynamic comparison of two aspirin formulations in the Caribbean: The ARC Study. Cardiol Ther. 2024;13(3):593–602. PMID: 39008026. PMCID: PMC11333668. https://doi.org/10.1007/s40119-024-00373-6
  26. Кобалава Ж.Д., Писарюк А.С., Филькова А.А., Тухсанбоев Е.С., Амирова А.Н., Корнейчук А.Д. с соавт. Эффективность ацетилсалициловой кислоты с содержанием буфера и ацетилсалициловой кислоты в кишечнорастворимой оболочке по воздействию на агрегацию тромбоцитов у пациентов со стабильной ишемической болезнью сердца и сахарным диабетом 2 типа (КАСКАД): одноцентровое наблюдательное сравнительное исследование. Российский кардиологический журнал. 2025;30(2):95–129. [Kobalava ZhD, Pisaryuk AS, Filkova AA, Tukhsanboev ES, Amirova AN, Korneichuk AD et al. Efficacy of buffered acetylsalicylic acid and enteric-coated acetylsalicylic acid on platelet aggregation in patients with chronic coronary syndrome and type 2 diabetes (CASCADE): Single-center observational comparative study. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2025;30(2):95–129 (In Russ.)]. EDN: KAUMEZ. https://doi.org/10.15829/1560-4071-2025-6282
  27. Sleem A, Effron MB, Stebbins A, Wruck LM, Marquis-Gravel G, Muñoz D et al. Effectiveness and safety of enteric-coated vs uncoated aspirin in patients with cardiovascular disease: A secondary analysis of the ADAPTABLE randomized clinical trial. JAMA Cardiol. 2023;8(11):1061–69. PMID: 37792369. PMCID: PMC10551818. https://doi.org/10.1001/jamacardio.2023.3364
  28. Барбараш О.Л., Карпов Ю.А., Панов А.В., Акчурин Р.С., Алекян Б.Г., Алехин М.Н. с соавт. Стабильная ишемическая болезнь сердца. Клинические рекомендации 2024. Российский кардиологический журнал. 2024;29(9):166–229. [Barbarash OL, Karpov YuA, Panov AV, Akchurin RS, Alekyan BG, Alekhin MN et al. 2024 Clinical practice guidelines for stable coronary artery disease. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2024;29(9):166–229 (In Russ.)]. EDN: HHJJUT. https://doi.org/10.15829/1560-4071-2024-6110
  29. Rao SV, O’Donoghue ML, Ruel M, Rab T, Tamis-Holland JE, Alexander JH et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the management of patients with acute coronary syndromes: A report of the American College of Cardiology / American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025;151(13):e771–e862. PMID: 40014670. https://doi.org/10.1161/cir.0000000000001309

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar
2. Fig. 1. Causes and risk factors for the development of a decreased response or lack of response to standard low doses of acetylsalicylic acid (75-100 mg per day)

Baixar (24KB)
Metadados
3. Fig. 2. Basic methods for determining the response to acetylsalicylic acid. Note: ASA – acetylsalicylic acid; AA – arachidonic acid activation.

Baixar (244KB)
Metadados

Declaração de direitos autorais © Bionika Media, 2025